Important Notice This article provides evidence-based commentary and research drawn from publicly available sources, legislation, case law and official reports as of 2026. It is intended for informational and educational purposes only. It does not constitute legal, medical or professional advice. Clinicians should apply their own professional judgement and refer to current NICE guidance, GMC standards and local protocols. Reliance on this content is at the reader’s own risk.
Introduction
Menstrual disorders are common and can significantly affect occupational functioning, yet their impact on work is frequently under-explored in clinical encounters. Endometriosis and adenomyosis each affect approximately one in ten women of reproductive age; PCOS and symptomatic fibroids are also prevalent; PMDD causes severe cyclical symptoms in a smaller proportion.
Symptoms such as severe dysmenorrhoea, heavy menstrual bleeding, chronic pelvic pain, fatigue, bloating and mood disturbance can impair concentration, physical stamina, emotional regulation and attendance.
The 2023 CIPD survey found 69% of women experiencing menstrual symptoms reported a negative work impact, rising sharply among those with diagnosed conditions. Over half had needed time off; many continued working while symptomatic (presenteeism).
These patterns matter clinically because work is a key determinant of health, identity and economic security. Prolonged diagnostic delays – historically averaging seven to nine years for endometriosis and still a concern – compound physical, psychological and occupational harm.
Clinical assessment and management A thorough history should routinely include occupational context: “How are your symptoms affecting your work, concentration or ability to carry out normal tasks?”
This is not extraneous; it forms part of holistic assessment of quality of life and functioning, consistent with NICE guidance on endometriosis (NG73), heavy menstrual bleeding (NG88) and PCOS.
Validating the patient’s experience counters the historical tendency to normalise or dismiss cyclical pain as “just periods”.
Management is multidisciplinary. Gynaecological input (hormonal therapies, surgical options for endometriosis/fibroids), pain management, endocrinology (PCOS), and psychological support (particularly for PMDD or secondary mental health effects) often need coordination.
Fertility implications and long-term health risks (anaemia, bone density, cardiovascular) should be discussed where relevant.
Treatment decisions should incorporate the patient’s priorities, including remaining in or returning to work.
Occupational health referral, with patient consent, can bridge clinical care and workplace adjustments. Clinicians may be asked to provide factual letters describing symptoms, functional limitations and likely duration or recurrence.
These letters support reasonable adjustment discussions but do not determine legal disability status; that is for employers and, ultimately, tribunals to assess on the evidence.
Systemic observations
Patients often describe fragmented care: multiple specialists addressing isolated symptoms without a joined-up view of how hormonal fluctuations, pain and fatigue interact with daily life and employment.
The renewed Women’s Health Strategy for England (2026) commits to specialist centres, community hubs, single-point gynaecology access and prioritised pathways for heavy periods and menstrual problems (including endometriosis, fibroids and adenomyosis).
These developments aim to reduce delays and improve integration, but implementation will take time and will benefit from clinicians actively considering occupational outcomes.
Clinicians can also support patients by signposting reliable information (NHS, NICE patient versions, specialist charities) and encouraging open dialogue with employers where safe.
Normalising discussion of menstrual health in consultations helps counter stigma that leads many women to hide symptoms at work.
For the patient’s lived experience and practical navigation of workplace rights, see the linked Patient article. For the organisational and policy response required from employers and regulators, see the Governance article.
Mandatory Disclaimer
This article is for general information and discussion only. It is not medical or legal advice, nor a substitute for professional advice. To contribute evidence, ideas, or corrections, please email womenshealthproject@outlook.com. Please do not share personal data when emailing. Individual cases cannot be reviewed. This project does not offer any form of legal service and cannot assist with complaints, claims or individual advocacy. This platform is independent and not affiliated with any law firm, regulator, inquiry or clinical body.
© 2026 Women’s Health Inquiry Project (WHIP). This article includes original analysis of material from publicly available national sources. It may not be reproduced without permission.
References
- CIPD (2023) Menstruation and support at work.
- NICE NG73 Endometriosis; NG88 Heavy menstrual bleeding; related PCOS guidance (current versions).
- Department of Health and Social Care (2026) Renewed Women’s Health Strategy for England.
- Parliament UK, Women and Equalities Committee (2024) Women’s reproductive health conditions.
- Ms S Pal v Accenture UK Ltd [2026] EAT 12 (for awareness of legal context around disability assessment).
- NHS and specialist charity clinical resources.